Cerus Corporation Share Price

Equities

CERS

US1570851014

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
1.71 USD +0.59% Intraday chart for Cerus Corporation +1.79% -20.83%
Sales 2024 * 179M 14.9B Sales 2025 * 203M 16.91B Capitalization 316M 26.36B
Net income 2024 * -20M -1.67B Net income 2025 * -9M -750M EV / Sales 2024 * 1.77 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.56 x
P/E ratio 2024 *
-15.5 x
P/E ratio 2025 *
-34.2 x
Employees 631
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.47%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cerus Corporation

1 day+0.59%
1 week+1.79%
Current month-9.52%
1 month-1.72%
3 months-8.56%
6 months+31.54%
Current year-20.83%
More quotes
1 week
1.61
Extreme 1.61
1.79
1 month
1.61
Extreme 1.61
1.99
Current year
1.59
Extreme 1.59
2.59
1 year
1.21
Extreme 1.205
3.08
3 years
1.21
Extreme 1.205
8.06
5 years
1.21
Extreme 1.205
8.87
10 years
1.21
Extreme 1.205
8.87
More quotes
Managers TitleAgeSince
Founder 80 19/91/19
Chief Executive Officer 57 01/95/01
Director of Finance/CFO 52 01/06/01
Members of the board TitleAgeSince
Director/Board Member 65 04/19/04
Chief Executive Officer 57 01/95/01
Founder 80 19/91/19
More insiders
Date Price Change Volume
26/24/26 1.71 +0.59% 387,036
25/24/25 1.7 +2.41% 951,750
24/24/24 1.66 -1.19% 590,027
23/24/23 1.68 -0.59% 781,359
22/24/22 1.69 +0.60% 824,401

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.71 USD
Average target price
4.2 USD
Spread / Average Target
+145.61%
Consensus